Skip to Content
Merck

Key Documents

View All Documentation

SML4254

AT7519

≥98% (HPLC), powder, CDK inhibitor

Synonym(s):

AT 7519, AT-7519, AT7519, N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide, 4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide, 4-[(2,6-Dichlorobenzoyl)amino]-N-4-piperidinyl-1H-pyrazole-3-carboxamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C16H17Cl2N5O2
CAS Number:
844442-38-2
Molecular Weight:
382.24
MDL number:
MFCD28977942
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Segment

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Application

AT7519 may be used to study its effects on cell viability and proliferation, cell cycle, apoptosis and pyroptosis in human glioblastoma cells.

Biochem/physiol Actions

AT7519 is a potent and selective cyclin dependent kinase (CDK) inhibitor (CDK5-p35/CDK2-CycA/CDK4-CycD1/CDK1-CycB IC50 = 18/44/67/190 nM; IC50 >10 μM against Aurora A, IR, MEK1, PDK1, c-abl) with antiproliferative activity in cancer cultures (IC50 = 82 nM/HCT116, 350 nM/A2780) and antitumor efficacy in mice in vivo (86% inhibition of A2780 xenograft tumor growth post 8-day treatment at 7.5 mg/kg b.i.d. i.p., 87% inhibition of HCT116 xenograft tumor growth post 10-day treatment at 9.1 mg/kg b.i.d. i.p.).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library